Vertex Pharmaceuticals price target raised to $425 from $400 at BofA » 07:42 VRTX, CRSP
We should be in both VRTX & CRSP.- We are not.
We should be in both VRTX & CRSP.- We are not.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
GBA Presents: House of Gummy-!
- Thread starter stonedinvestor
- Start date
I had PEP calls I rode in to earnings and dumped on the spike around $164, they were not worth the risk. It’s $157 again. Did you see DVA responses to Semi glut?Yes all wants, snacking, boozing, sex have been eliminated. Everyone is super thin and taking in few nutrients, the Cows no longer fart and we are properly set up for the alien assimilation.
Ozampa = Alien pill.
My premise on LW puts at $101 on strong earnings was classic Goku and Lizard King. $2.1 to $18!
Stoney it’s 8:38 AM(5:38 AM) do you know where your stocks are?
Mister Car Wash upgraded to Outperform from Neutral at Baird » 05:10 MCW
Nuscale Power initiated with a Buy at B. Riley » 08:39 SMR
Centrus Energy initiated with a Buy at B. Riley » 08:36 LEU
HealthEquity price target raised to $110, named a 'Best Idea' at Guggenheim » 08:33 HQY, HIMS
-- Why is HIMS referenced here? Perhaps also on Guggenheim list?
Nuscale Power initiated with a Buy at B. Riley » 08:39 SMR
Centrus Energy initiated with a Buy at B. Riley » 08:36 LEU
HealthEquity price target raised to $110, named a 'Best Idea' at Guggenheim » 08:33 HQY, HIMS
-- Why is HIMS referenced here? Perhaps also on Guggenheim list?
Typical stoney day--
Oct 13 (Reuters) - Amylyx Pharmaceuticals said on Friday the European Union medicines regulator for the second time declined to recommend a marketing authorisation for the company's drug to treat amyotrophic lateral sclerosis (ALS).
The decision comes after Amylyx in June requested a formal re-examination of the initial negative opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
The company said it will focus on completing the late-stage study of the drug, based on which it will seek the EU's approval, and detailed results are expected by mid-2024.
The drug, which has been approved by the U.S. Food and Drug Administration (FDA), is a combination of generic compounds sodium phenylbutyrate and taurursodiol that work together to prevent nerve cells in the brain and spinal cord from dying prematurely.
Amylyx's drug has also been granted conditional approval in Canada.
Which means BUY THE OTHER ONE!!
Oct 13 (Reuters) - Amylyx Pharmaceuticals said on Friday the European Union medicines regulator for the second time declined to recommend a marketing authorisation for the company's drug to treat amyotrophic lateral sclerosis (ALS).
The decision comes after Amylyx in June requested a formal re-examination of the initial negative opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
The company said it will focus on completing the late-stage study of the drug, based on which it will seek the EU's approval, and detailed results are expected by mid-2024.
The drug, which has been approved by the U.S. Food and Drug Administration (FDA), is a combination of generic compounds sodium phenylbutyrate and taurursodiol that work together to prevent nerve cells in the brain and spinal cord from dying prematurely.
Amylyx's drug has also been granted conditional approval in Canada.
Which means BUY THE OTHER ONE!!
The days of collecting Funko pops, so fun!
Funko
Funko
- The Trade: Funko, Inc. (NASDAQ:FNKO) 10% owner Chan Kenneth Hsiangtze acquired a total of 225,782 shares an average price of $6.84. To acquire these shares, it cost around $1.54 million.
- What’s Happening: Funko reported a second-quarter earnings miss and issued weak guidance.
- What Funko Does: Funko Inc is an US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through the movie, TV show, video game, musician, or sports team.”
--TerrAscend to host investor day » 08:55 TSNDF
--Ardelyx to present updates for XPHOZAH at Kidney Week 2023 » 08:07 ARDX,
ARDX- FRIDAY GUMMY-!
Ardelyx, Inc. (ARDX) @$3.40
NasdaqGM - NasdaqGM Real Time Price.
3.2900-0.2500(-7.06%)
At close: October 12 04:00PM EDT
3.3988+0.11(+3.31%)
Pre-Mark
--Ardelyx to present updates for XPHOZAH at Kidney Week 2023 » 08:07 ARDX,
ARDX- FRIDAY GUMMY-!
Ardelyx, Inc. (ARDX) @$3.40
NasdaqGM - NasdaqGM Real Time Price.
3.2900-0.2500(-7.06%)
At close: October 12 04:00PM EDT
3.3988+0.11(+3.31%)
Pre-Mark
Stoney, asking for a friend. Would you hold the NVO Dec-March $100-$110 calls?
Description
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis-infused artisan edibles. It also operates retail dispensaries under the Apothecarium brand name in California, Pennsylvania, and New Jersey. In addition, the company owns various synergistic businesses under Gage Growth, Pinnacle, TerrAscend NJ, Ilera Healthcare, HMS Health and HMS Processing, Valhalla Confections, State Flower, Arise Bioscience Inc., and TerrAscend Canada brands. It serves medical and legal adult-use markets. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. The company produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis-infused artisan edibles. It also operates retail dispensaries under the Apothecarium brand name in California, Pennsylvania, and New Jersey. In addition, the company owns various synergistic businesses under Gage Growth, Pinnacle, TerrAscend NJ, Ilera Healthcare, HMS Health and HMS Processing, Valhalla Confections, State Flower, Arise Bioscience Inc., and TerrAscend Canada brands. It serves medical and legal adult-use markets. The company was incorporated in 2017 and is headquartered in Mississauga, Canada.
TerrAscend Corp. (TSNDF) Gummy #2-
Other OTC - Other OTC
1.8400-0.0150(-0.8086%)
At close: October 12
Won't move like the other I don't think // but they beat their earn number and have an investor day....
Other OTC - Other OTC
1.8400-0.0150(-0.8086%)
At close: October 12
Won't move like the other I don't think // but they beat their earn number and have an investor day....